Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study. Study SPAIN.

Trial Profile

Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study. Study SPAIN.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2011

At a glance

  • Drugs Antiasthmatics; Budesonide/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Feb 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual patient number (791) added as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top